PDC-1421
Botanical
Evidence outlook · lead readout
NCT02395978 · Major Depressive Disorder
The lead study reported mixed results: some prespecified endpoints were met and others were not. The tier describes the design; the rationale below says what the study found.
NCT02395978: The treatment phase was randomized, triple-blind, placebo-controlled, and included 60 participants across three groups, although the groups were small. Its primary clinical endpoint, change in MADRS score at week 6, was not statistically significant compared with placebo, so the findings provide limited evidence of benefit. Label revised to mixed on 2026-09-02: one dose arm shows a numerical advantage the sponsor reports as significant, the other shows none.
The registered primary (MADRS change at week 6 vs placebo, Part II) spans two dose arms: 2-capsule arm -13.19 vs placebo -9.2; 1-capsule arm -9.21 vs -9.2 (registry, ITT, ~20 per arm). The sponsor's 2019-06-05 release reports the high-dose arm met the prespecified primary; the registry results carry no p-values.
Also in development:Attention Deficit Hyperactivity Disorder · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02395978 NCT02395978 · Major Depressive Disorder The treatment phase was randomized, triple-blind, placebo-controlled, and included 60 participants across three groups, although the groups were small. Its primary clinical endpoint, change in MADRS score at week 6, was not statistically significant compared with placebo, so the findings provide limited evidence of benefit. Label revised to mixed on 2026-09-02: one dose arm shows a numerical advantage the sponsor reports as significant, the other shows none. The registered primary (MADRS change at week 6 vs placebo, Part II) spans two dose arms: 2-capsule arm -13.19 vs placebo -9.2; 1-capsule arm -9.21 vs -9.2 (registry, ITT, ~20 per arm). The sponsor's 2019-06-05 release reports the high-dose arm met the prespecified primary; the registry results carry no p-values. Registry: NCT02395978 | 2 | Change of Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Week 6 Compared to Placebo for Part II. 2019-03-12 | Change of Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Week 6 Compared to Placebo for Part II. (From Baseline to Week 6): Part II: 2 PDC-1421 Capsule — ITT population: -13.19 score on a scale (Standard Deviation 9.68); PP population: -13.4 score on a scale (Standard Deviation 9.7) | Part II: 1 PDC-1421 Capsule Plus 1 Placebo — ITT population: -9.21 score on a scale (Standard Deviation 8.32); PP population: -10.4 score on a scale (Standard Deviation 5.18) vs Part II: 2 Placebo — ITT population: -9.2 score on a scale (Standard Deviation 7.98); PP population: -8.6 score on a scale (Standard Deviation 7.61) | Partial signal | link ↗ |
View 1 more trial
NCT01774045 NCT01774045 · Major Depressive Disorder This was a randomized, triple-blind, placebo-controlled study, but it enrolled only 30 participants unevenly split (23 active, 7 placebo) and tracked only safety and tolerability measures over 72 hours, not a clinical efficacy outcome or a formal statistical test. Its registered primary outcome on ClinicalTrials.gov is "Number of Dose Limiting Toxicity of Physical Examination" (with 4 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak. Registry: NCT01774045 | 1 | Number of Dose Limiting Toxicity of Physical Examination (baseline to 72 hours); Number of Dose Limiting Toxicity of Electrocardiograph (baseline to 72 hours); Number of Dose Limiting Toxicity of Vital Sign (baseline to 72 hours); Number of Dose Limiting Toxicity of Laboratory Values (baseline to 72 hours); Number of Dose Limiting Toxicity of Columbia-Suicide Severity Rating Scale (C-SSRS) (baseline to 72 hours) 2013-07 | Number of Dose Limiting Toxicity of Physical Examination (baseline to 72 hours): PDC-1421 0 participants | Placebo Control 0 participants | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Attention Deficit Hyperactivity Disorder: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| PDC-1421: this drug | Phase 2 | Botanical | Polygalae radix extract (active components: tenuifolin, polygalasaponins, etc.) | not yet graded | No reviewed efficacy summary in this indication | |
| Centanafadine (Simtriyo) | Approved | Small molecule | Serotonin/norepinephrine/dopamine transporter | Reliable signal | NCT05257265: ADHD-RS-5 change at week 6: -18.50 [0.93] centanafadine 328.8 mg vs -14.15 [0.93] placebo (p = .0006); 164.4 mg did not meet the primary endpoint | |
| Viloxazine (Qelbree) | Approved | Small molecule | norepinephrine transporter | Reliable signal | NCT04016779: Efficacy of SPN-812 on Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) as Assessed by the Adult ADHD Investigator Symptom Rating Scale (AISRS) Total Score (Baseline and Week 6): Placebo -11.7 units on a scale (Standard Error 0.9) | SPN-812 -15.5 units on a scale (Standard Error 0.91) NCT03247543: Efficacy of SPN-812 Assessed by Attention-Deficit/Hyperactivity Disorder Rating Scale, 5th Edition (ADHD-RS-5) (Baseline and Week 8 (End of Study)): Placebo -11.7 units on a scale (Standard Error 1.48) | 200mg SPN-812 -17.6 units on a scale (Standard Error 1.43) | 400mg SPN-812 -17.5 units on a scale (Standard Error 1.52) | |
| Solriamfetol (Sunosi) | Phase 3 | Small molecule | Dopamine/norepinephrine transporter | not yet graded | No reviewed efficacy summary in this indication | |
| Lysergide Tartrate (LSD) (DT120) | Phase 2 | Small molecule | 5-HT2A receptor | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow PDC-1421 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.